Jason R Healy1,2, Lori S Hart1, Alexander L Shazad1, Maria E Gagliardi1, Matthew Tsang1, Jimmy Elias1, Jacob Ruden1, Alvin Farrel1,3, Jo Lynne Rokita1,3,4, Yimei Li1,5, Anastasia Wyce6, Olena Barbash6, Vandana Batra1,5, Minu Samanta1, John M Maris1,5,7, Robert W Schnepp8,9. 1. Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Department of Bioinformatics and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 4. Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 6. Cancer Epigenetics RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. 7. Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 8. Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 9. Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
Abstract
BACKGROUND: The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that Bromodomain and extraterminal (BET) inhibitors can inhibit MYCN expression and suppress MYCN-amplified neuroblastoma in vivo. Furthermore, alterations within RAS-MAPK (mitogen-activated protein kinase) signaling play significant roles in neuroblastoma initiation, maintenance, and relapse, and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors demonstrate efficacy in subsets of neuroblastoma preclinical models. Finally, hyperactivation of RAS-MAPK signaling has been shown to promote resistance to BET inhibitors. Therefore, we examined the antitumor efficacy of combined BET/MEK inhibition utilizing I-BET726 or I-BET762 and trametinib in high-risk neuroblastoma. PROCEDURE: Utilizing a panel of genomically annotated neuroblastoma cell line models, we investigated the in vitro effects of combined BET/MEK inhibition on cell proliferation and apoptosis. Furthermore, we evaluated the effects of combined inhibition in neuroblastoma xenograft models. RESULTS: Combined BET and MEK inhibition demonstrated synergistic effects on the growth and survival of a large panel of neuroblastoma cell lines through augmentation of apoptosis. A combination therapy slowed tumor growth in a non-MYCN-amplified, NRAS-mutated neuroblastoma xenograft model, but had no efficacy in an MYCN-amplified model harboring a loss-of-function mutation in NF1. CONCLUSIONS: Combinatorial BET and MEK inhibition was synergistic in the vast majority of neuroblastoma cell lines in the in vitro setting but showed limited antitumor activity in vivo. Collectively, these data do not support clinical development of this combination in high-risk neuroblastoma.
BACKGROUND: The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that Bromodomain and extraterminal (BET) inhibitors can inhibit MYCN expression and suppress MYCN-amplified neuroblastoma in vivo. Furthermore, alterations within RAS-MAPK (mitogen-activated protein kinase) signaling play significant roles in neuroblastoma initiation, maintenance, and relapse, and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors demonstrate efficacy in subsets of neuroblastoma preclinical models. Finally, hyperactivation of RAS-MAPK signaling has been shown to promote resistance to BET inhibitors. Therefore, we examined the antitumor efficacy of combined BET/MEK inhibition utilizing I-BET726 or I-BET762 and trametinib in high-risk neuroblastoma. PROCEDURE: Utilizing a panel of genomically annotated neuroblastoma cell line models, we investigated the in vitro effects of combined BET/MEK inhibition on cell proliferation and apoptosis. Furthermore, we evaluated the effects of combined inhibition in neuroblastoma xenograft models. RESULTS: Combined BET and MEK inhibition demonstrated synergistic effects on the growth and survival of a large panel of neuroblastoma cell lines through augmentation of apoptosis. A combination therapy slowed tumor growth in a non-MYCN-amplified, NRAS-mutated neuroblastoma xenograft model, but had no efficacy in an MYCN-amplified model harboring a loss-of-function mutation in NF1. CONCLUSIONS: Combinatorial BET and MEK inhibition was synergistic in the vast majority of neuroblastoma cell lines in the in vitro setting but showed limited antitumor activity in vivo. Collectively, these data do not support clinical development of this combination in high-risk neuroblastoma.
Authors: Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades Journal: Cell Date: 2011-09-01 Impact factor: 41.582
Authors: Alexandre Puissant; Stacey M Frumm; Gabriela Alexe; Christopher F Bassil; Jun Qi; Yvan H Chanthery; Erin A Nekritz; Rhamy Zeid; William Clay Gustafson; Patricia Greninger; Matthew J Garnett; Ultan McDermott; Cyril H Benes; Andrew L Kung; William A Weiss; James E Bradner; Kimberly Stegmaier Journal: Cancer Discov Date: 2013-02-21 Impact factor: 39.397
Authors: Anton Henssen; Kristina Althoff; Andrea Odersky; Anneleen Beckers; Richard Koche; Frank Speleman; Simon Schäfers; Emma Bell; Maike Nortmeyer; Frank Westermann; Katleen De Preter; Alexandra Florin; Lukas Heukamp; Annika Spruessel; Kathy Astrahanseff; Sven Lindner; Natalie Sadowski; Alexander Schramm; Lucile Astorgues-Xerri; Maria E Riveiro; Angelika Eggert; Esteban Cvitkovic; Johannes H Schulte Journal: Clin Cancer Res Date: 2015-12-02 Impact factor: 12.531
Authors: Jo Lynne Harenza; Maura A Diamond; Rebecca N Adams; Michael M Song; Heather L Davidson; Lori S Hart; Maiah H Dent; Paolo Fortina; C Patrick Reynolds; John M Maris Journal: Sci Data Date: 2017-03-28 Impact factor: 6.444
Authors: Risa Niemas-Teshiba; Ryosuke Matsuno; Larry L Wang; Xao X Tang; Bill Chiu; Jasmine Zeki; Jeannine Coburn; Kimberly Ornell; Arlene Naranjo; Collin Van Ryn; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Shahab Asgharzadeh; Naohiko Ikegaki; Hiroyuki Shimada Journal: Oncotarget Date: 2017-12-15
Authors: Joseph Lehár; Andrew S Krueger; William Avery; Adrian M Heilbut; Lisa M Johansen; E Roydon Price; Richard J Rickles; Glenn F Short; Jane E Staunton; Xiaowei Jin; Margaret S Lee; Grant R Zimmermann; Alexis A Borisy Journal: Nat Biotechnol Date: 2009-07-05 Impact factor: 54.908
Authors: Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo Journal: Int J Mol Sci Date: 2021-11-28 Impact factor: 5.923